TriangleNab-Paclitaxel (NCT06439693)
Nab-Paclitaxel trial for Breast Cancer Female (NCT06439693). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with breast cancer metastatic at diagnosis, HER2 IHC3+ in breast and metastatic biopsies, and no prior systemic therapy except up to six weeks of first-line taxane/trastuzumab/pertuzumab.
The idea: sequential treatments target HER2 before cancer worsens. Taxane/trastuzumab/pertuzumab precedes trastuzumab-deruxtecan, then tucatinib/T-DM1, then trastuzumab/pertuzumab/tucatinib. These include antibodies carrying cancer-killing drugs and a HER2 signaling blocker. Researchers test about ninety-three weeks of treatment followed by stopping HER2 therapy and monitoring.
This phase 2 study plans 72 patients. Nancy Lin leads at Dana-Farber in Boston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.